

China-based Jiangsu Hengrui Pharma launches new subsidiary Luzsana Biotech

May 19, 2022 | News

Luzsana to co-develop medicines with parent company Hengrui Pharma and commercialize in North America, Europe and Japan



Chinese firm Jiangsu Hengrui Pharmaceuticals has announced that it is launching Luzsana Biotechnology (Luzsana), a global, purpose-driven innovative medicines company committed to delivering medicines that are available, accessible and affordable to more people around the world.

Luzsana, a wholly owned subsidiary of Hengrui Pharma, is a global development and commercialization biotechnology organization. Luzsana has developed a strategic plan with Hengrui Pharma that provides the company access to a world-class pipeline of more than 250 clinical studies in areas of high unmet medical need, such as oncology, cardiovascular, metabolic/diabetes, pain management, immunology and liver and renal disease.

Through their unique relationship, Luzsana can partner with Hengrui Pharma to assess and hand select assets from Hengrui Pharma's robust pipeline of more than 250 clinical studies across multiple therapeutic areas for global co-development and commercialization. Luzsana also will have access to 16 Hengrui Pharma research and development centers with more than 5,400 research staff. Luzsana has initially selected 11 high-potential oncology and non-oncology programs that span all phases of development, from preclinical to phase 3 for co-development. While the company's initial pipeline is weighted heavily toward oncology with 8 out of 11 programs, Luzsana intends to further diversify its pipeline over time.